168.74 % to Target, Wedbush Reconfirms ‘”Buy”’ Rating on miRagen Therapeutics Inc (MGEN) Shares Today

March 14, 2018 - By Vivian Park

 168.74 % to Target, Wedbush Reconfirms ‘

miRagen Therapeutics Inc (MGEN) Rating Reaffirmed

Wedbush now has a $19.0 target price on shares of miRagen Therapeutics Inc (MGEN). The target price gives a potential upside of 168.74 % from the last stock close of miRagen Therapeutics Inc (MGEN). This rating was released in a report on Friday morning.

Miragen Therapeutics, Inc. (NASDAQ:MGEN) Ratings Coverage

Among 7 analysts covering Miragen Therapeutics (MGEN), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Miragen Therapeutics has $19.0 highest and $13.0 lowest target. $16.40’s average target is 131.97% above currents $7.07 stock price. Miragen Therapeutics had 11 analyst reports since February 21, 2017 according to SRatingsIntel. Wedbush initiated the shares of MGEN in report on Tuesday, February 21 with “Outperform” rating. The company was maintained on Monday, August 14 by Chardan Capital Markets. The company was maintained on Monday, October 16 by Wedbush. The firm has “Buy” rating by Wedbush given on Friday, August 18. As per Friday, February 2, the company rating was maintained by FBR Capital. The stock of Miragen Therapeutics, Inc. (NASDAQ:MGEN) has “Buy” rating given on Friday, December 1 by Wedbush. The firm has “Buy” rating given on Thursday, January 11 by Oppenheimer.

The stock increased 0.71% or $0.05 during the last trading session, reaching $7.07. About 223,355 shares traded. Miragen Therapeutics, Inc. (MGEN) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. The company has market cap of $207.16 million. The Company’s two lead product candidates, MRG-106 and MRG-201 are in Phase 1 clinical trials. It currently has negative earnings. The companyÂ’s clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in various blood cancers.

More notable recent Miragen Therapeutics, Inc. (NASDAQ:MGEN) news were published by: Streetinsider.com which released: “miRagen Therapeutics (MGEN) Announces Proposed 7M Share Common Offering” on February 05, 2018, also Globenewswire.com with their article: “miRagen Therapeutics to Participate in Upcoming Investor Conferences” published on March 05, 2018, Seekingalpha.com published: “Miragen Therapeutics May Provide Long-Term Alpha Within The RNA Space” on February 01, 2018. More interesting news about Miragen Therapeutics, Inc. (NASDAQ:MGEN) were released by: Globenewswire.com and their article: “miRagen Therapeutics to Present at the Cantor Fitzgerald Global Healthcare …” published on September 01, 2017 as well as Globenewswire.com‘s news article titled: “miRagen Therapeutics, Inc. Prices Public Offering of Common Stock” with publication date: February 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.